Why ABION’s ABN202 may be aiming beyond TROP2 antibody-drug conjugate resistance
ABION’s ABN202 showed preclinical promise against TROP2 ADC resistance at AACR 2026. Read what this could mean for solid tumor oncology.
Can Calidi Biotherapeutics, Inc.’s RedTail platform solve the solid tumor T-cell engager problem?
Calidi Biotherapeutics, Inc. unveils new RedTail and TROP-2 data at AACR 2026. Read what this means for solid tumor immunotherapy and CLD-401 next.
What the NEOK002 IND milestone changes for Biocytogen, NEOK Bio, and ADC competition
NEOK002 has cleared the FDA IND stage. Read why this bispecific ADC matters for solid tumors, clinical strategy, and the next phase of ADC competition.
Why Precision Biologics is betting on tumor-specific neoepitopes to reshape monoclonal antibody cancer therapy
Precision Biologics highlights tumor-specific monoclonal antibodies at Festival of Biologics USA. Discover how neoepitope targeting could reshape cancer therapy.
Is Propanc Biopharma’s PRP proenzyme platform a credible challenger in the pancreatic oncology market?
Can Propanc Biopharma’s PRP therapy disrupt pancreatic cancer treatment? Explore the science, risks, and market implications of this emerging oncology approach.
Biocytogen and IDEAYA Biosciences push IDE034 into the clinic as dual-antigen ADC strategies mature
IDEAYA Biosciences doses first patient in IDE034 Phase 1 trial. Discover what this bispecific ADC means for solid tumor therapy.
What Kainova Therapeutics’ latest financing reveals about the future of CCR8-targeted cancer therapies
Find out how Kainova Therapeutics’ $32M CAD funding could reshape GPCR-based immuno-oncology and inflammation drug development.
What Propanc Biopharma’s PRP signals about alternative mechanisms in the crowded pancreatic cancer pipeline
Can PRP’s proenzyme approach change pancreatic cancer treatment strategy? Explore what Propanc Biopharma’s data means for oncology innovation.
Avacta Therapeutics (LSE: AVCT) advances FAP-targeting drug conjugate AVA6103 into Phase 1: What’s at stake?
Avacta Therapeutics (LSE: AVCT) has received Investigational New Drug (IND) clearance from the United States Food and Drug Administration for AVA6103 (also known as FAP-Exd), its second clinical-stage asset developed using the company’s proprietary pre|CISION platform. The IND clearance enables the start of a Phase 1 trial evaluating the safety, tolerability, and dose parameters of […]
Can CRISPR editing of NRF2 reverse resistance in head and neck squamous cell carcinoma?
CorriXR’s new data show CRISPR-based NRF2 disruption restores chemo response in squamous tumors. Find out what this could mean for HNSCC treatment.